May 16, 2022 13:00 ET | Source: DelveInsight Business Research LLP DelveInsight Business Research LLP

New York, USA, May 16, 2022 (GLOBE NEWSWIRE) -- Extensive Stage Small Cell Lung Cancer Pipeline Review | Clinical Trial Analysis by DelveInsight

First-line therapies in the treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC) currently consist of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. New treatments are under development in order to improve the prognosis of ES-SCLC. There are approximately more than 35+ companies investigating the potential therapies for the treatment of ES-SCLC including Bristol-Myers Squibb, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, BeiGene, Hoffmann-La Roche, Lee's Pharmaceutical, and several others.

DelveInsight’s 'Extensive Stage Small Cell Lung Cancer Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Extensive Stage Small Cell Lung Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Extensive Stage Small Cell Lung Cancer pipeline domain.

Key Takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

Request a sample and discover the recent advances in the Extensive Stage Small Cell Lung Cancer treatment @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook

The Extensive Stage Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Extensive Stage Small Cell Lung Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Extensive Stage Small Cell Lung Cancer pipeline landscape.

Extensive Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (SCLC) is a cancer that has progressed to other parts of the body, such as the other lung or the brain. Without the treatment, the typical Extensive Stage Small Cell Lung Cancer life expectancy is two to four months. With treatment, the Extensive Stage Small Cell Lung Cancer life expectancy climbs to six to twelve months, with a 5-year survival rate of up to 4%.

In the early stage, the person will not have Extensive Stage Small Cell Lung Cancer symptoms. But, as cancer advances, people may develop a chronic cough or recurring lung infections. Extensive-stage small cell lung cancer symptoms are classified as those affecting the lungs, those induced by para neoplastic syndromes (abnormal immunological or hormone activity triggered by the tumor), and those associated with metastasis.

Among the major Extensive Stage Small Cell Lung Cancer causes include smoking. The Extensive Stage Small Cell Lung Cancer diagnosis include several tests such as laboratory test, biopsy, chest x-ray, CT scan, physical exam, sputum cytology, bronchoscopy, and others. The preferred Extensive Stage Small Cell Lung Cancer treatment strategy for the patients is a combination of chemotherapy and immunotherapy drugs. Find out more about drugs for Small Cell Lung Cancer treatment @ Extensive Stage Small Cell Lung Cancer Drugs

A snapshot of the Extensive Stage Small Cell Lung Cancer Pipeline Drugs mentioned in the report:

Learn more about the novel and emerging Extensive Stage Small Cell Lung Cancer pipeline therapies @ Extensive Stage Small Cell Lung Cancer Clinical Trials

Extensive Stage Small Cell Lung Cancer Therapeutics Assessment

The Extensive Stage Small Cell Lung Cancer Pipeline report proffers an integral view of the Extensive Stage Small Cell Lung Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report 

Dive deep into rich insights for new drugs for small cell lung cancer, visit @ Extensive Stage Small Cell Lung Cancer Treatment Drugs 

For further information on the Extensive Stage Small Cell Lung Cancer pipeline therapeutics, reach out @ New Drugs for Small Cell Lung Cancer 

Non-Small Cell Lung Cancer (NSCLC) Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast - 2030 report delivers an in-depth understanding of Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key Non-Small Cell Lung Cancer companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.

Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2022, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Non-Small-Cell Lung cancer companies involved such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Sanofi, and others.

Small Cell Lung Cancer Market

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends, and key Small Cell Lung Cancer companies involved such as Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and many others.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-Met Mutated Non-Small Cell Lung Cancer companies such as Novartis, Apollomics Inc., Abbvie, among others.

EGFR Non-Small Cell Lung Cancer Pipeline

EGFR Non-Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR Non-Small Cell Lung Cancer companies such as Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, among others.

Artificial Lung Market Insight, Competitive Landscape and Market Forecast, 2026 report delivers an in-depth understanding of Artificial Lung and the historical and forecasted Artificial Lung market trends, and key players involved such as Xenios, Miromatrix Medical, Lung Biotechnology PBC, Haemair, Michigan Critical Care Consultants, MedArray, Breethe, ALung Technologies, McGowan Institute for Regenerative Medicine, and The Charles Stark Draper Laboratory.

“Hypertrophic Scar Market” research report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Henry Ford Health System, Gladerma, Phio Pharmaceuticals, and others.

“Secondary Hyperparathyroidism Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Sanwa Kagaku Kenkyusho, OPKO Health, TaiRx, Amgen, and others.

“Obsessive-Compulsive Disorder Market” research report delivers an in-depth understanding of the disorder, historical and forecasted epidemiology as well as the Obsessive-Compulsive Disorder market size, share, and trends in the 7MM. Some of the key companies in the Obsessive-Compulsive Disorder Therapeutics Market include Pfizer, GlaxoSmithKline, Eli Lilly and Company, Biohaven Pharmaceuticals, and others.

Degenerative Disc Disease (DDD) Market

“Degenerative Disc Disease (DDD) Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Degenerative Disc Disease market size, share, and trends in the 7MM. Some of the key companies in the Degenerative Disc Disease Market include DiscGenics, Kuros Biosciences, Mesoblast, Ankasa Therapeutics, and others.

“Periodontal Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Periodontal Disease market size, share, and trends in the 7MM. Some of the key companies in the Periodontal Disease Market include D and D Pharmatech, Amyndas Pharmaceuticals, AngioLab, Denteric, Dexcel Pharma Technologies, Yuhan Corporation, and others. 

“IgG4-Related Disease Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the IgG4-Related Disease market size, share, and trends in 7MM. Some of the key companies in the IgG4-Related Disease Market include Bristol-Myers Squibb, Xencor, Principia Biopharma, Viela Bio, Horizon Therapeutics, and others. 

“Nicotine Addiction Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Nicotine Addiction market size, share, and trends in the 7MM. Some of the key companies in the Nicotine Addiction Therapeutics Market include Axsome Therapeutics, Achieve Life Sciences, Novo Nordisk, and others.

Small Cell Lung Cancer Treatment Market Non-Small Cell Cancer Market Lung Cancer and its Increasing Global Burden

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News